In a patient with known systemic lupus erythematosus presenting with fever, how should the cause be evaluated and what is the appropriate management?

SLE with Fever: Evaluation and Management

In an SLE patient presenting with fever, infection is the most common cause (occurring in 48-66% of cases), followed by disease flare (34-45% of cases), and you must aggressively pursue differentiation using specific biomarkers and clinical parameters before initiating treatment. 1, 2

Differential Diagnosis Framework

The fever in SLE patients stems from three primary etiologies:

• Infection (most common): 48-66% of febrile episodes 1, 2

  • Respiratory tract infections dominate (62.6% of infections)
  • Urinary tract (8.6%)
  • Skin/mucosa (8.3%)
  • Tuberculosis, viral, and fungal infections are significant

• Disease flare: 34-45% of cases 1, 2

• Combined infection + flare: 8 cases in one series 1

Diagnostic Approach: Key Discriminating Biomarkers

Use the following laboratory parameters to distinguish infection from flare:

Markers Favoring Infection:

• Procalcitonin (PCT): Best single predictor 3
  • Cut-off ≥0.90 ng/mL: 84.6% sensitivity, 85.7% specificity
  • Odds ratio 224.37 for infection prediction
• Neutrophil Z: Novel marker with excellent performance 4
  • When combined with C3 or anti-dsDNA: AUC 0.86-0.88
• CRP elevation: Significantly higher in infection 3, 1
• Neutrophil-to-lymphocyte ratio (NLR): Elevated in infection 3
• ESR/CRP ratio: Lower in infection (inversely correlated) 3

Markers Favoring Disease Flare:

• Low complement C3 and C4 5, 1
• Elevated anti-dsDNA antibodies 5
• Higher SLEDAI-2K scores 2
• Duration of fever: Shorter fever duration suggests flare 5

Validated Risk Calculator:

A three-variable model provides AUC 0.92 for flare prediction 5:

• Days of fever
• Anti-dsDNA antibody titers
• CRP levels

Mandatory Screening (Per EULAR Guidelines)

Before initiating or escalating immunosuppression 6:

• HIV, HCV, HBV: Based on risk factors
• Tuberculosis: According to local guidelines
• CMV: Consider in selected patients during treatment

Monitor for severe immunosuppression markers:

• Severe neutropenia (<500 cells/mm³)
• Severe lymphopenia (<500 cells/mm³)
• Low IgG (<500 mg/dL)

Management Algorithm

If Infection is Suspected/Confirmed:

1. Obtain cultures before antibiotics (blood, urine, respiratory as indicated)
2. Initiate broad-spectrum antibiotics immediately
3. Consider tuberculosis, opportunistic infections in immunosuppressed patients
4. Azathioprine use within 6 months increases infection risk 2

If Disease Flare is Confirmed:

Prednisone dosing for SLE fever 2:

• ≤100 mg/day suppresses fever in 80.6% of patients
• Response typically occurs within 1-5 days
• Failure to respond suggests:
  • Severe lupus encephalopathy
  • Hemophagocytic syndrome
  • Concurrent infection

Critical Pitfall:

Never assume fever is solely from disease activity without ruling out infection. The immunosuppressed state of SLE patients, particularly those on azathioprine or high-dose steroids, creates substantial infection vulnerability. Missing an infection while escalating immunosuppression can be fatal.

Practical Clinical Approach

Order immediately:

• PCT (most important single test)
• Complete blood count with differential for NLR
• CRP and ESR
• Complement C3, C4
• Anti-dsDNA antibodies
• Blood, urine, and site-specific cultures

If PCT ≥0.90 ng/mL + elevated CRP + normal/high C3: Treat as infection until proven otherwise

If PCT <0.90 ng/mL + low C3/C4 + elevated anti-dsDNA + short fever duration: Consider disease flare, but maintain high suspicion for occult infection

Composite scoring using Neutrophil Z + C3 or anti-dsDNA provides superior discrimination and should be utilized when available 4.